Physician profile
Philip Wong
NPI 1932168267
$2,500.75
in general payments reported to CMS, 2019-2025
32 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $160 · 2021: $216 · 2022: $312 · 2023: $510 · 2024: $166 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $479.17 | 2019-2024 | Xiaflex, Edex, Aveed |
| Urogen Pharma, INC. | $315.07 | 2022-2023 | Jelmyto |
| Astellas Pharma US INC | $180.15 | 2019-2025 | Xtandi, Myrbetriq |
| Boston Scientific Corporation | $164.27 | 2019-2025 | Spaceoar Vue System - 10ml, Axonics |
| Olympus America INC. | $139.83 | 2023-2025 | Itind System |
| Procept Biorobotics Corporation | $126.56 | 2023-2025 | Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $106.33 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $87.46 | 2019-2025 | Erleada |
| Axonics, INC. | $72.77 | 2022-2023 | Axonics |
| Allergan, INC. | $68.02 | 2019-2021 | |
| Neotract INC. | $60.75 | 2019 | |
| Antares Pharma, INC. | $57.61 | 2025 | Xyosted |
| Coloplast Corp | $54.21 | 2019-2020 | |
| Rochester Medical Corporation | $51.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.02 | 2024-2025 | Adstiladrin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $44.97 | 2019-2025 | Provenge |
| Endo USA, INC. | $44.85 | 2024 | Xiaflex |
| Teleflex LLC | $44.23 | 2021-2022 | |
| Tolmar, INC. | $44.17 | 2024 | |
| Abbvie INC. | $41.18 | 2025 | |
| Immunitybio, INC. | $36.59 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $32.06 | 2023 | Andexxa |
| Merck Sharp & Dohme LLC | $31.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.73 | 2025 | |
| Metuchen Pharmaceuticals | $26.81 | 2020 | |
| Myriad Genetic Laboratories, INC. | $24.26 | 2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $17.53 | 2025 | |
| Ambu INC. | $15.77 | 2025 | |
| Pfizer INC. | $15.68 | 2019 | |
| Angiodynamics, INC. | $15.63 | 2022 | |
| Amgen INC. | $15.27 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.